Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 13/20 | 1.00 |
| ▸ | NQO2 | P16083 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26989162 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL4392665 | 0.81 | MTNR1A (0.70) | MTNR1AMTNR1BNQO2HSD17B10 | |
| SCHEMBL1310030 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1308979 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1311849 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HSD17B10 | |
| SCHEMBL4393644 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HSD17B10 | |
| SCHEMBL18239761 | 0.75 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL26989677 | 0.74 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2HSD17B10 | |
| SCHEMBL1309768 | 0.73 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2TP53HSD17B10 | |
| SCHEMBL1308837 | 0.72 | MTNR1A (0.57) | MTNR1AMTNR1BNQO2TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053462-B2 | Indole derivative and application thereof | SOMEI MASANORI | 2011-11-08 | — | — | US | disclosed |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20070197629-A1 | Indole derivative and application thereof | SOMEI MASANORI | 2007-08-23 | — | — | US | disclosed |
| US-5763471-A | TREATS PSYCHIATARIC AND BRAIN DISORDERS | CEMAF (FR) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MTNR1A 261/4885MTNR1B 180/4885NQO2 1905/4885 |
| US-20070197629-A1 | Indole derivative and application thereof | ARL1, IDO1, AIPL1 | MTNR1A 143/4885MTNR1B 287/4885NQO2 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.